Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
|Articles|June 2, 2003
- Pharmaceutical Technology-06-02-2003
- Volume 27
- Issue 6
Enhancement of the Dissolution Rate and Bioavailability of Glipizide through Cyclodextrin Inclusion Complex
Author(s)Adel M. Aly, PhD
This study characterized the interaction between glipiide and cyclodextrins and documented the influence of three tablet formulations on the blood glucose levels of mice.
Advertisement
Articles in this issue
over 23 years ago
June 2003over 23 years ago
From Genome Exploration to Drug Developmentover 23 years ago
Are you ready for Gen3over 23 years ago
Formulation Development of a Nucleotide Phosphoramidateover 23 years ago
Outsourcing OutlookAdvertisement
Related to this article
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
Univar Solutions scientists developed a lidocaine cream built on starch, sorbitol, coconut oil, and beeswax that matched a commercial benchmark on viscosity, assay, and hydration.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Nitrosamine Problems and Industry Solutions: PharmTech Explained
2
AAPS PharmSci 360 2026: E&L Standards Harmonization
3
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
4
Ask the Expert: Choosing Ingredient Suppliers
5